Clinical Reviews in Allergy & Immunology

, Volume 32, Issue 2, pp 178–183

The Heart and APS

Authors

    • Instituto Nacional de Cardiología Ignacio ChávezUniversidad Nacional Autónoma de México
    • ABC Medical Center
Article

DOI: 10.1007/s12016-007-0013-z

Cite this article as:
Amigo, M. Clinic Rev Allerg Immunol (2007) 32: 178. doi:10.1007/s12016-007-0013-z

Abstract

The heart is a target organ in antiphospholipid syndrome (APS). Endocardial disease, intracardiac thrombosis, myocardial involvement including coronary heart disease and microvascular thrombosis, as well as pulmonary hypertension have all been described in APS patients. Valvular involvement is the most common manifestation with a prevalence of 82% detected by transesophageal echocardiography. Symmetrical, nodular thickening of the mitral and/or aortic valves is characteristic. Anticoagulant/antiplatelet treatment is ineffective in terms of valvular lesion regression. Some patients require cardiac valve replacement. However, patients with APS have shown an increased perioperative morbidity and mortality. Intracardiac thrombosis, although a rare complication, can cause pulmonary and systemic emboli. Differential diagnosis with myxoma may be very difficult.

Keywords

Valve diseaseAntiphospholipid syndromeIntracardiac thrombosis

Copyright information

© Humana Press Inc. 2007